2024
Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)
Sankhe K, Tumati S, Perin J, Rivet L, Vieira D, Rosenberg P, Herrmann N, Shade D, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J, Lanctôt K. Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). International Psychogeriatrics 2024, 100012. DOI: 10.1016/j.inpsyc.2024.100012.Peer-Reviewed Original ResearchBoston Naming TestMini-Mental State ExamCategory fluencyMild-to-moderate AD patientsClinically significant apathyCognitive change scoresModerate AD patientsHopkins Verbal LearningVerbal learningDigit spanNaming TestVerbal fluencySignificant apathyTrail MakingCognitive changesMeasure apathyMethylphenidateCognitionCognitive scoresState ExamMini-MentalChange scoresApathyAD patientsTrial 2
2023
Blood‐based biomarkers for predicting treatment response in the Apathy in Dementia Methylphenidate Trial 2 randomized clinical trial
Tumati S, Vieira D, Bawa K, Andreazza A, Mintzer J, Scherer R, Rosenberg P, van Dyck C, Padala P, Brawman‐Mintzer O, Porsteinsson A, Lerner A, Craft S, Levey A, Burke W, Perin J, Shade D, Herrmann N, Lanctôt K. Blood‐based biomarkers for predicting treatment response in the Apathy in Dementia Methylphenidate Trial 2 randomized clinical trial. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.079161.Peer-Reviewed Original ResearchCost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).
Lanctôt K, Chen C, Mah E, Kiss A, Li A, Shade D, Scherer R, Vieira D, Coulibaly H, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Burke W, Mintzer J, Herrmann N. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). International Psychogeriatrics 2023, 35: 664-672. PMID: 37066690, PMCID: PMC10579450, DOI: 10.1017/s1041610223000327.Peer-Reviewed Original ResearchConceptsCost-consequence analysisTreatment of apathyFive-level questionnaireTrial 2Quality of lifeBinary logistic regressionPlacebo groupPlacebo treatmentMethylphenidate treatmentSignificant apathyHealth utilityResource utilization costsAlzheimer's diseaseLogistic regressionMethylphenidateTime interactionLevel questionnaireHealthcare systemCost predictorsMeasures analysisPatientsTreatmentDiseaseMonthsUtilization costs
2017
[O1–01–06]: MEASURING APATHY IN ALZHEIMER'S DISEASE IN THE APATHY IN DEMENTIA METHYLPHENIDATE TRIAL 2 (ADMET 2): A COMPARISON OF INSTRUMENTS
Lanctot K, Scherer R, Li A, Rosenberg P, Herrmann N, Lerner A, Padala P, Brawman‐Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Burke W, Mintzer J. [O1–01–06]: MEASURING APATHY IN ALZHEIMER'S DISEASE IN THE APATHY IN DEMENTIA METHYLPHENIDATE TRIAL 2 (ADMET 2): A COMPARISON OF INSTRUMENTS. Alzheimer's & Dementia 2017, 13: p184-p184. DOI: 10.1016/j.jalz.2017.07.038.Peer-Reviewed Original Research